Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is uterine adenosarcoma?
Uterine adenosarcoma is an uncommon cancer of the uterus that is a 'mixed' tumor — it contains benign-looking glands (the 'adeno' part) woven together with a low-grade cancerous connective tissue (the 'sarcoma' part). It often grows as a polyp-like mass inside the uterine cavity and may show up as abnormal bleeding, a mass protruding through the cervix, or pelvic pain, in women across a wide age range. Most adenosarcomas are low-grade and have a good outlook. The crucial exception is 'sarcomatous overgrowth,' meaning more than a quarter of the tumor is pure high-grade sarcoma — this, along with deep growth into the muscle of the uterine wall, sharply raises the risk of recurrence and spread. Surgery is the main treatment, and pathology determines who needs more.
The main types
Doctors group uterine adenosarcoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Adenosarcoma without sarcomatous overgrowth | The common, lower-risk form. Behaves relatively gently and is usually cured by surgery, especially when caught early. |
| Adenosarcoma with sarcomatous overgrowth | More than 25% of the tumor is pure high-grade sarcoma. The most important adverse feature — much higher risk of recurrence and distant spread. |
| With deep myometrial invasion | The tumor grows deeply into the muscular uterine wall, which also raises the risk of return and may prompt added treatment. |
Staging, in plain terms
Adenosarcoma is staged with the FIGO system for uterine sarcomas, which is based on how far the tumor has grown: whether it is limited to the lining or has invaded the muscular wall, spread within the pelvis, or reached distant organs. Two pathology features — sarcomatous overgrowth and deep muscle invasion — are weighed heavily alongside the stage because they predict behavior so strongly.
| FIGO staging for uterine sarcoma | What it generally means |
|---|---|
| Stage I | Confined to the uterus. Subdivided by whether the tumor stays in the lining or invades the muscular wall. Most adenosarcomas are found here, with a good outlook. |
| Stage II | Spread beyond the uterus but still within the pelvis (for example to the cervix or supporting tissues). |
| Stage III | Spread into the abdomen or to pelvic or para-aortic lymph nodes. |
| Stage IV | Invades the bladder or bowel, or has spread to distant organs such as the lungs. |
The standard of care
Uterine Adenosarcoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (the primary treatment)
Total hysterectomy — removing the uterus, usually with the cervix — is the foundation, often with removal of the ovaries and tubes especially after menopause. Complete removal cures most early, low-risk tumors with no further treatment.
Radiation for higher-risk disease
Pelvic radiation or vaginal brachytherapy may be added when there is sarcomatous overgrowth, deep muscle invasion, or disease beyond the uterus, to reduce the chance of pelvic recurrence.
Chemotherapy for aggressive or advanced tumors
Chemotherapy is considered for tumors with sarcomatous overgrowth or for recurrent and metastatic disease, where the high-grade sarcoma component drives the risk.
Hormonal therapy in selected cases
Because some adenosarcomas carry hormone receptors, anti-hormone (for example aromatase-inhibitor) therapy is an option for certain recurrent or advanced low-grade tumors.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide. After surgery for a higher-risk adenosarcoma, pelvic radiation or vaginal brachytherapy targets the areas most likely to harbor leftover cells — the pelvis and the top of the vagina — to lower the chance the cancer returns there. Brachytherapy delivers its dose from inside the body, concentrating it exactly where it is needed and sparing nearby organs. Treatment is painless, given over a series of short sessions, and leaves no radioactivity in the body afterward.
The main ways radiation is delivered for uterine adenosarcoma:
Pelvic external-beam radiation (IMRT/IGRT)
Image-guided, intensity-modulated radiation treats the pelvis when there is a higher risk of local return, shaping the dose around the bladder, bowel, and rectum to limit side effects.
Vaginal brachytherapy
A radiation source is placed inside the vagina for a short time to deliver a concentrated dose to the top of the vagina — a common site of recurrence — while sparing surrounding organs.
Stereotactic body radiation (SBRT)
Delivers a few high, focused doses to an isolated recurrence or metastasis when surgery is not the best choice.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Management with and without sarcomatous overgrowth: Studies confirm that sarcomatous overgrowth is the single most important pathology feature: 5-year survival is about 50-60% with overgrowth or deep muscle invasion versus 70-80% for early disease without it, guiding who needs added radiation or chemotherapy.[1]
Gynecologic Oncology (ScienceDirect S0090825812009936)
Updated treatment review: A current literature review reaffirmed surgery as the mainstay, with radiation directed at higher-risk pelvic disease and chemotherapy reserved for sarcomatous-overgrowth, recurrent, or metastatic tumors.[2]
Gynecology and Pelvic Medicine (AME, Nigro et al.)
NCI uterine sarcoma treatment summary (PDQ): The NCI's physician summary frames hysterectomy as primary therapy for uterine sarcomas including adenosarcoma, with individualized use of radiation, chemotherapy, and hormonal therapy based on stage and pathology.[3]
NCI PDQ — Uterine Sarcoma Treatment
Common questions
What is 'sarcomatous overgrowth' and why does it matter so much? It means that more than a quarter of the tumor is made of pure, high-grade sarcoma rather than the usual gentler mix. It is the most important predictor of how an adenosarcoma will behave — tumors with it are far more likely to come back or spread, so your team may recommend radiation or chemotherapy in addition to surgery.
Will I need anything besides surgery? Many women with early, low-risk adenosarcoma are cured by hysterectomy alone. Added radiation or chemotherapy is considered when the pathology shows sarcomatous overgrowth, deep invasion of the uterine muscle, or spread beyond the uterus.
Can my ovaries be preserved? It depends on your age, the tumor's features, and your wishes. Removing the ovaries is common, especially after menopause, but preservation is sometimes discussed for younger women with early, low-risk tumors. This is an individual decision to make with your gynecologic oncologist.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.